Woodline Partners’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Woodline Partners’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-235,100	Closed	-$169K	–	874
2022 Q3	$169K	Hold	235,100	–	–	﹤0.01%	657
2022 Q2	$125K	Hold	235,100	–	–	﹤0.01%	631
2022 Q1	$207K	Buy	+235,100	New	+$262K	﹤0.01%	551

Other funds holding DNA.WS

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $49M AUM 17.65% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

JFGLC

Johnson Financial Group LLC (Colorado) Denver, Colorado $1.86B AUM 22.33% 1-Year Est. Return

Woodline Partners's DNA.WS Position: Q4 2022 in Review

Woodline Partners sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2022, closing a stake of 235,100 shares — an estimated $169K sold.

Woodline Partners first reported a position in DNA.WS in Q1 2022 and held it in 3 quarters. The position peaked at $207K in Q1 2022. 44 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2022.

Woodline Partners reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2022 after selling out during the quarter.
Woodline Partners sold 235,100 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2022, an estimated $169K.
Woodline Partners first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q1 2022 and held it in 3 quarters.
Woodline Partners's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $207K in Q1 2022.
44 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2022.

Based on Woodline Partners's 13F filing for Q4 2022, filed 14 Feb 2023.